Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Summary

This study aims to evaluate the efficacy and safety of Tislelizumab combined with concurrent chemoradiotherapy in the treatment of cervical cancer patients with cervical mass \> 4cm and regional lymph node metastasis, paracervical invasion and regional lymph node metastasis, stage IIIA, stage IIIB, and stage IVA. To provide a clinical reference for finding a safe and effective individualized treatment plan to improve the survival prognosis of locally advanced cervical cancer patients.

Timeline

Start

2022-12-01

Primary completion

2024-12-31

Completion

2025-12-31

Drugs

Indications